Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02829723
Title Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | ISR | ESP | CHE

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Sarah Cannon Research Institute Sarah Cannon Research Nashville Tennessee 37203 United States Details
UT M.D Anderson Cancer Center Houston Texas 77030 United States Details
Mays Cancer Ctr Uthsa Mdacc San Antonio Texas 78229 United States Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Nagoya Aichi 466 8560 Japan Details
Novartis Investigative Site Koto ku Tokyo 135 8550 Japan Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Hospitalet de LLobregat Catalunya 08907 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Zurich 8091 Switzerland Details
Novartis Investigative Site Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field